Answers are grounded in this paper and cite their sources.
Liposomal bupivacaine (LB) is a long-acting analgesic implemented within multimodal and enhanced recovery after surgery (ERAS) pathways in plastic and reconstructive surgery. While it has been popularized as an opioid-sparing alternative for postoperative pain management, LB costs far more to acquire than standard bupivacaine, and its contribution to downstream costs is difficult to isolate. This scoping review mapped the study designs, cost constructs, methods, and results of cost measures linked to LB in plastic and reconstructive surgery. Eligible studies gave LB to patients undergoing plastic and reconstructive surgery and reported at least one quantitative measure of cost or charge. Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) and Joanna Briggs Institute (JBI) guidance, MEDLINE, the Cochrane Library, Web of Science, Embase, and ScienceDirect were searched for English-language studies published from January 2012 through August 2024. Data were charted using Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 as an extraction scaffold. As a declared extension of scoping methodology, the cost endpoint was appraised using American Society of Plastic Surgeons and the Oxford Centre for Evidence-Based Medicine (ASPS/OCEBM) levels of evidence, Cochrane risk of bias (RoB) 2 for randomized trials, and Risk Of Bias In Non-randomized Studies - of Interventions (ROBINS-I) for non-randomized studies. Three randomized trials and five non-randomized trials met the inclusion criteria. Cost constructs ranged from drug acquisition price and patient willingness-to-pay to charges derived from hospital length of stay (LOS), cost-to-charge-converted direct costs, data-warehouse costs, and claims costs compared with diagnosis-related group (DRG)-expected values. The only directly comparable element amongst the included studies was the LB acquisition price. This scoping review reveals that the cost evidence for LB in plastic and reconstructive surgery comprises widely heterogeneous endpoints that are not comparable with one another. Economic value-based positioning of LB in multimodal analgesia and ERAS pathways will require further prospective, adequately powered trials and full economic evaluations that declare their perspective, use contemporary comparators, standardize the price year, extend the time horizon beyond the index care event, and report uncertainty.
No takes yet. Share an insight, caveat, or question.
Berger et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: